Table 2.
Outcome of intent-to-treat and per-protocol analyses on day 28 with PCR distinction between recrudescence and reinfection.
| Comparator1 | Treatment | PCR-uncorrected outcome | PCR-corrected outcom | ||
|---|---|---|---|---|---|
| OR (ITT) | OR (PP) | OR (ITT) | OR (PP) | ||
| AS-AQ | AQ | 0.71 (0.31-1.60) |
0.70 (0.26-1.85) |
1.24 (0.43-3.56) |
3.85 (0.41-35.6) |
| AS-AQ | AS-SP | 0.60 (0.23-1.31) |
0.55 (0.20-1.53) |
0.98 (0.32-3.00) |
2.94 (0.30-29.2) |
| AQ-SP | AS-MQ | 0.68 (0.26-1.75) |
0.13 (0.01-1.10) |
1.62 (0.50-5.24) |
- - |
| AS-AQ | AM-LM | 0.26 (0.07-1.03) |
0.36 (0.06-1.92) |
0.13 (0.01-1.10) |
0.12 (0-2.04) |
| AS-CD | AS-SP | 0.30* (0.13-0.62) |
0.24* (0.09-0.65) |
0.39* (0.17-0.85) |
0.37 (0.12-1.20) |
| AS-AQ | DH-PP | 0.32* (0.12-0.80) |
0.12* (0.02-0.52) |
0.61 (0.22-1.66) |
0.28 (0.05-1.36) |
Treatment outcome on day 28 for studies conducted in 2005-2007. OR (ITT), odds ratio in the case of the intention-to-treat (ITT) analysis, where the total number of patients enrolled was considered. OR (PP), odds ratio in the per-protocol (PP) analysis.
1Treatment taken as reference. Odds-ratios (OR, 95% confidence intervals in parentheses) were calculated for the pairs of ACT in each randomized study, except for the study in 2005 (AS-AQ vs AQ). Asterisks denote P < 0.05.